And this was talked about in the recent American College of Physicians guidelines on the of depression. There’s a whole category of partial response that is of equal or even greater prevalence than complete TRD. You get a number that’s consistent with other numbers out there, that about a quarter of have TRD, meaning don’t respond to 2 or more therapies with different medicines. Of those were left, 40% of responded to second-line treatment. ![]() From what we heard from Dr Thase, 50% of responded to first-line treatment. Neil Skolnik, MD: I’m going to distinguish between who have a partial response, which we see a lot in primary care, and who have TRD, where there’s that drop off in the STAR*D trial. Megan Maroney, PharmD, BCPP: Dr Skolnik, how common is TRD? How prevalent is it? And how do the rates differ across different genders and ethnic groups? As we look at data sets, being able to join that with a medical record or at least a data warehouse associated with the medical record is very helpful. Or we might see, as Dr Thase mentioned, they’re on an SSRI and you added aripiprazole, but we don’t know for certain that person’s responding to treatment. ![]() We’ll know that someone’s been on antidepressants for a period. What are the outcomes associated with it? So claims data just that, and your results and are only as good as the data you have. We’re using it in terms of data analytics to determine the economics of things. Megan Maroney, PharmD, BCPP: Dr Cannon, what are some of the limitations associated with implementing a TRD definition in claims databases?Įric Cannon, PharmD, FAMCP: I don’t know that we implement the definition in a claims database.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |